You need to be logged in to view this video

Emerald Health: Capitalizing on Wellness and Medical Opportunities for Cannabis

Released on Monday, May 14, 2018•CANNABIS

Share
Facebook Twitter LinkedIn SMS

Hear from our newly appointed CEO, Chris Wagner, on how Emerald Health Therapeutics is positioning itself to be one of the leading producers and product innovators in the growing global trend to legalize cannabis for the expanding global medicinal market and for the legal recreational use in Canada starting in 2018.

Chris Wagner

Emerald Health Therapeutics, CEO

Chris Wagner is the CEO of Emerald Health Therapeutics. He has spent more than 25 years in marketing pharmaceutical products and building biotechnology companies. Mr. Wagner worked with Eli Lilly for 10 years, rising to Global Team Leader, where he helped develop and commercialize 15 biologic and small molecule products. He left Eli Lilly to join Aspreva Pharmaceuticals Inc. as vice president, Business Development and Global Marketing. During his five years at Aspreva, the company's valuation increased from $2 million to $1 billion; it was later acquired by Galenica. Mr. Wagner most recently served as chairman, president and CEO of Contextual Genomics Inc, a molecular bioinformatics company that has worked with AstraZeneca, Pfizer and Sanofi to develop genomic cancer diagnostic products. He has a BSc in organic chemistry from the University of British Columbia and completed executive programs in finance and marketing research at Wharton Business School and Kellogg School of Management.